Patents by Inventor Steven A. Porcelli
Steven A. Porcelli has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10111950Abstract: The invention is directed to compositions and methods related to proteins that are physically associated with ceramide-like glycolipids for use as activators of NKT cells. The compositions and methods of the present invention are useful for the prevention and treatment of diseases.Type: GrantFiled: June 3, 2016Date of Patent: October 30, 2018Assignees: Vaccinex, Inc., Albert Einstein College of Medicine, Inc.Inventors: Steven A. Porcelli, Maurice Zauderer
-
Publication number: 20160346384Abstract: The invention is directed to compositions and methods related to proteins that are physically associated with ceramide-like glycolipids for use as activators of NKT cells. The compositions and methods of the present invention are useful for the prevention and treatment of diseases.Type: ApplicationFiled: June 3, 2016Publication date: December 1, 2016Applicants: Vaccinex, Inc., Albert Einstein College of Medicine, Inc.Inventors: Steven A. Porcelli, Maurice Zauderer
-
Patent number: 9371352Abstract: The invention is directed to compositions and methods related to proteins that are physically associated with ceramide-like glycolipids for use as activators of NKT cells. The compositions and methods of the present invention are useful for the prevention and treatment of diseases.Type: GrantFiled: March 14, 2013Date of Patent: June 21, 2016Assignees: VACCINEX, INC., ALBERT EINSTEIN COLLEGE OF MEDICINE, INC.Inventors: Steven A. Porcelli, Maurice Zauderer
-
Patent number: 9139809Abstract: The invention is directed compositions and methods related to bacterial cells physically associated with ceramide-like glycolipids. The invention allows for delivery of ceramide-like glycolipid adjuvants directly to the same cells that become infected with a bacterial vaccine. The compositions and methods of the present invention are useful for the prevention and treatment of diseases.Type: GrantFiled: January 8, 2010Date of Patent: September 22, 2015Assignee: Albert Einstein College of Medicine of Yeshiva UniversityInventors: Steven A. Porcelli, Manjunatha M. Venkataswamy
-
Publication number: 20150224188Abstract: Provided are compositions comprising a plurality of isolated mycobacterium membrane vesicles, and methods of use thereof, and methods of improving the efficacy of immunizations. Throughout this application various publications are referred to by number in parentheses. Full citations for the references may be found at the end of the specification. The disclosures of each of these publications, and also the disclosures of all patents, patent application publications and books recited herein, are hereby incorporated by reference in their entirety into the subject application to more fully describe the art to which the subject invention pertains.Type: ApplicationFiled: September 23, 2013Publication date: August 13, 2015Applicant: ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITYInventors: Arturo Casadevall, Rafael Prados-Rosales, Steven A. Porcelli, William R. Jacobs
-
Publication number: 20140329766Abstract: The present disclosure pertains to antimicrobial compositions for intravenous administration to patients who have experienced a serious brain trauma, to reduce the risk of occurrence of post-trauma microbial infections. The antimicrobial compositions comprise an ?-galacytosylceramide compound and one or more excipients. The present disclosure also pertains to the use of ?-galacytosylceramide compounds for the manufacture of antimicrobial medicaments for intravenous administration to patients with serious brain traumas. The present disclosure also pertains to methods for the prophylactic use of the antimicrobial compositions to reduce the risks of occurrence of post-trauma microbial infections.Type: ApplicationFiled: November 28, 2012Publication date: November 6, 2014Inventors: Connie Hoi Yee Wong, Paul Kubes, Steven A. Porcelli
-
Publication number: 20140227296Abstract: The invention is directed to compositions and methods related to proteins that are physically associated with ceramide-like glycolipids for use as activators of NKT cells. The compositions and methods of the present invention are useful for the prevention and treatment of diseases.Type: ApplicationFiled: March 14, 2013Publication date: August 14, 2014Inventors: Steven A. Porcelli, Maurice Zauderer
-
Patent number: 8591918Abstract: Provided are mycobacteria deleted in at least a portion of a region 3 ESAT-6-like gene cluster. Also provided are mycobacteria comprising a mutation in an roc-1 gene. Additionally, vaccines comprising these mycobacteria are provided. Further provided are methods of making a recombinant mycobacterium, methods of inducing an immune response in a mammal, methods of inhibiting IL-12 production in a mammal, and methods of stimulating IL-12 production in a mammal. Vaccine adjuvants are also provided, as are methods of inducing immunity to a target antigen in a mammal.Type: GrantFiled: March 10, 2008Date of Patent: November 26, 2013Assignee: Albert Einstein College of Medicine of Yeshiva UniversityInventors: William R. Jacobs, Jr., Kari Sweeney, Dee Dao, Steven A. Porcelli, John Chan, Tsungda Hsu
-
Publication number: 20130164325Abstract: The invention is directed compositions and methods related to bacterial cells that are physically associated with ceramide-like glycolipids for use as antigen carriers for heterologous antigens. The invention further relates to methods of incorporating ceramide-like glycolipid to bacterial cell walls. The compositions and methods of the present invention are useful for the prevention and treatment of diseases.Type: ApplicationFiled: July 6, 2011Publication date: June 27, 2013Applicant: Albert Einstein College of Medicine of Yeshiva UniversityInventors: Steven A. Porcelli, Manjunatha M. Venkataswamy
-
Patent number: 8394388Abstract: Provided are recombinant mycobacteria having a mutation in an nlaA gene or in a nuoG gene. Also provided are isolated and purified nlaA proteins and nuoG proteins from a mycobacterium. Additionally provided are isolated and purified nucleic acids comprising a recombinant nlaA gene or a recombinant nuoG gene. Further provided are methods of inducing an immune response in a mammal and methods of making a recombinant mycobacterium using the nlaA gene or the nuoG gene.Type: GrantFiled: January 12, 2006Date of Patent: March 12, 2013Assignee: Albert Einstein College of Medicine of Yeshiva UniversityInventors: William R. Jacobs, Jr., Steven A. Porcelli, Volker Briken, Miriam Braunstein
-
Publication number: 20120141533Abstract: Provided are mycobacteria deleted in at least a portion of a region 3 ESAT-6-like gene cluster. Also provided are mycobacteria comprising a mutation in an roc-1 gene. Additionally, vaccines comprising these mycobacteria are provided. Further provided are methods of making a recombinant mycobacterium, methods of inducing an immune response in a mammal, methods of inhibiting IL-12 production in a mammal, and methods of stimulating IL-12 production in a mammal. Vaccine adjuvants are also provided, as are methods of inducing immunity to a target antigen in a mammal.Type: ApplicationFiled: March 10, 2008Publication date: June 7, 2012Inventors: William R. Jacobs, JR., Kari Sweeney, Dee Dao, Steven A. Porcelli, John Chan, Tsungda Hsu
-
Patent number: 8101191Abstract: Provided are mycobacteria comprising (a) a mutation that is not in a SecA2 gene that attenuates the virulence of the mycobacteria in a mammalian host, and (b) a mutation in a SecA2 gene that eliminates SecA2 activity. Also provided are mycobacteria that comprise a mutation in a SecA2 gene that eliminates SecA2 activity, where the mycobacteria are not Mycobacterium tuberculosis or Mycobacterium smegmatis. Additionally provided are methods of inducing an immune response in a mammal and methods of inducing an immune response to a pathogenic mycobacterium in a human using the above mycobacterial mutants.Type: GrantFiled: January 11, 2007Date of Patent: January 24, 2012Assignees: Albert Einstein College of Medicine of Yeshiva University, The University of North Carolina at Chapel HillInventors: William R. Jacobs, Jr., Steven A. Porcelli, Miriam Braunstein
-
Patent number: 8022043Abstract: ?-Galactosylceramides and glycosylceramides (“ceramide-like glycolipids”) that modulate NK T cells. The ceramide-like glycolipids vary in the cytokines induced in NK T cells and vary in the antigen-presenting cells that are capable of efficiently presenting the compounds to NK T cells. Pharmaceutical compositions of the ceramide-like glycolipids are provided, as are pharmaceutical compositions of the ceramide-like glycolipids combined with dendritic cells. Methods utilizing the ceramide-like glycolipids in vaccines, to activate NK T cells, to stimulate the immune system, and to treat mammals are also provided. The invention also provides methods of evaluating a compound for its ability to activate an NK T cell in the presence of a cell expressing a CD1d protein.Type: GrantFiled: April 23, 2007Date of Patent: September 20, 2011Assignee: Albert Einstein College of Medicine of Yeshiva UniversityInventor: Steven A. Porcelli
-
Publication number: 20100297185Abstract: Provided are recombinant mycobacteria having a mutation in an nlaA gene or in a nuoG gene. Also provided are isolated and purified nlaA proteins and nuoG proteins from a mycobacterium. Additionally provided are isolated and purified nucleic acids comprising a recombinant nlaA gene or a recombinant nuoG gene. Further provided are methods of inducing an immune response in a mammal and methods of making a recombinant mycobacterium using the nlaA gene or the nuoG gene.Type: ApplicationFiled: January 12, 2006Publication date: November 25, 2010Inventors: William R. Jacobs, JR., Steven A. Porcelli, Volker Briken, Miriam Braunstein
-
Patent number: 7772380Abstract: ?-Galactosylceramides and glycosylceramides (“ceramide-like glycolipids”) that modulate NK T cells. The ceramide-like glycolipids vary in the cytokines induced in NK T cells and vary in the antigen-presenting cells that are capable of efficiently presenting the compounds to NK T cells. Pharmaceutical compositions of the ceramide-like glycolipids are provided, as are pharmaceutical compositions of the ceramide-like glycolipids combined with dendritic cells. Methods utilizing the ceramide-like glycolipids in vaccines, to activate NK T cells, to stimulate the immune system, and to treat mammals are also provided. The invention also provides methods of evaluating a compound for its ability to activate an NK T cell in the presence of a cell expressing a CD1d protein.Type: GrantFiled: August 26, 2005Date of Patent: August 10, 2010Assignee: Albert Einstein College of Medicine of Yeshiva UniversityInventor: Steven A. Porcelli
-
Publication number: 20100183549Abstract: The invention is directed compositions and methods related to bacterial cells physically associated with ceramide-like glycolipids. The invention allows for delivery of ceramide-like glycolipid adjuvants directly to the same cells that become infected with a bacterial vaccine. The compositions and methods of the present invention are useful for the prevention and treatment of diseases.Type: ApplicationFiled: January 8, 2010Publication date: July 22, 2010Applicant: Albert Einstein College of Medicine of Yeshiva UniversityInventors: Steven A. Porcelli, Manjunatha M. Venkataswamy
-
Publication number: 20090110696Abstract: Provided are mycobacteria comprising (a) a mutation that is not in a SecA2 gene that attenuates the virulence of the mycobacteria in a mammalian host, and (b) a mutation in a SecA2 gene that eliminates SecA2 activity. Also provided are mycobacteria that comprise a mutation in a SecA2 gene that eliminates SecA2 activity, where the mycobacteria are not Mycobacterium tuberculosis or Mycobacterium smegmatis. Additionally provided are methods of inducing an immune response in a mammal and methods of inducing an immune response to a pathogenic mycobacterium in a human using the above mycobacterial mutants.Type: ApplicationFiled: January 11, 2007Publication date: April 30, 2009Inventors: William R. Jacobs, JR., Steven A. Porcelli, Miriam Braunstein
-
Publication number: 20070238673Abstract: ?-Galactosylceramides and glycosylceramides (“ceramide-like glycolipids”) that modulate NK T cells. The ceramide-like glycolipids vary in the cytokines induced in NK T cells and vary in the antigen-presenting cells that are capable of efficiently presenting the compounds to NK T cells. Pharmaceutical compositions of the ceramide-like glycolipids are provided, as are pharmaceutical compositions of the ceramide-like glycolipids combined with dendritic cells. Methods utilizing the ceramide-like glycolipids in vaccines, to activate NK T cells, to stimulate the immune system, and to treat mammals are also provided. The invention also provides methods of evaluating a compound for its ability to activate an NK T cell in the presence of a cell expressing a CD1d protein.Type: ApplicationFiled: April 23, 2007Publication date: October 11, 2007Inventor: Steven Porcelli
-
Patent number: 7063844Abstract: Provided are CD-1 presented antigens, compositions, cells, inhibitors and methods relating to the use of hydrophobic antigen presentation by CD1 molecules, including: methods for detecting the presence of a CD1-presented hydrophobic antigen in a sample; methods for isolating such CD1-presented antigens and isolated antigens; vaccines containing CD1-presented antigens and vaccination methods; methods of blocking CD1 antigen presentation; methods of identifying and/or isolating CD1 blocking agents and the isolated CD1 blocking agents; methods of inducing CD1 expression; and T-cells for use in the methods disclosed herein.Type: GrantFiled: May 21, 2001Date of Patent: June 20, 2006Assignee: The Brigham and Women's Hospital, Inc.Inventors: Steven A. Porcelli, Michael B. Brenner, Evan M. Beckman, Stephen T. Furlong
-
Publication number: 20060052316Abstract: ?-Galactosylceramides and glycosylceramides (“ceramide-like glycolipids”) that modulate NK T cells. The ceramide-like glycolipids vary in the cytokines induced in NK T cells and vary in the antigen-presenting cells that are capable of efficiently presenting the compounds to NK T cells. Pharmaceutical compositions of the ceramide-like glycolipids are provided, as are pharmaceutical compositions of the ceramide-like glycolipids combined with dendritic cells. Methods utilizing the ceramide-like glycolipids in vaccines, to activate NK T cells, to stimulate the immune system, and to treat mammals are also provided. The invention also provides methods of evaluating a compound for its ability to activate an NK T cell in the presence of a cell expressing a CD1d protein.Type: ApplicationFiled: August 26, 2005Publication date: March 9, 2006Inventor: Steven Porcelli